Bjorn Herpers

Bjorn Herpers

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2021 in Biofouling
Verified
Journal Article
Open access
JKJesse W.P. Kuiper
Jesse W.P. Kuiper
JHJolanda M. A Hogervorst
Jolanda M. A Hogervorst
BHBjorn Herpers
Bjorn Herpers
Astrid BakkerAstrid Bakker
Astrid Bakker
JKJenneke Klein-Nulend
Jenneke Klein-Nulend
BKBastiaan Krom
Bastiaan Krom
In this in vitro study the effect of XZ.700, a new endolysin, on methicillin resistant Staphylococcus aureus (MRSA) biofilms grown on titanium was evaluated. Biofilms of S. aureus USA300 were grown statically and under flow, and treatment with XZ.700 was compared with povidone-iodine (PVP-I) and gentamicin. To evaluate the cytotoxic effects of XZ.700 and derived biofilm lysates, human osteocyte-like cells were exposed to biofilm supernatants, and metabolism and proliferation were quantified. XZ.700 showed a significant, concentration dependent reduction in biofilm viability, compared with carrier controls. Metabolism and proliferation of human osteocyte-like cells were not affected by XZ.700 or lysates, unlike PVP-I and gentamicin lysates which significantly inhibited proliferation. Using time-lapse microscopy, rapid biofilm killing and removal was observed for XZ.700. In comparison, PVP-I and gentamicin showed slower biofilm killing, with no apparent biofilm removal. In conclusion, XZ.700 reduced MRSA biofilms, especially under flow condition, without toxicity for surrounding bone cells.

8 March 2016 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
DSDennis Souverein
Dennis Souverein
SESjoerd M. Euser
Sjoerd M. Euser
BHBjorn Herpers
Bjorn Herpers
BDBram Diederen
Bram Diederen
PHPatricia Houtman
Patricia Houtman
JBJeroen W. Den Boer
Jeroen W. Den Boer
This paper describes (1) the Highly Resistant Gram Negative Rod (HR-GNR) prevalence rate, (2) their genotypes, acquired resistance genes and (3) associated risk factors of HR-GNR colonization among the hospitalized population in the Dutch region Kennemerland. Between 1 October 2013 and 31 March 2014, cross-sectional prevalence measurements were performed in three regional hospitals as part of each hospitals infection control program. Rectal swabs were analyzed at the Regional Public Health Laboratory Kennemerland by direct culturing. Genotypes and acquired resistance genes of positive isolates were determined using Whole Genome Sequencing with the MiSeq instrument (Illumina). Association between several independent variables and HR-GNR positivity was examined using logistic regression models. Out of 427 patients, 24 HR-GNR positive isolates were recovered from 22 patients, resulting in a regional HR-GNR colonization prevalence (95 % CI) of 5.2 % (3.6–7.9). Of these 22 positive patients, 15 were Extended Spectrum Beta-Lactamase (ESBL) positive (3.5 % (2.1–5.7)), 7 patients were positive for a Fluoroquinolones and Aminoglycosides (Q&A) resistant Enterobacteriaceae (1.6 % (0.8–3.3)) and from one patient (0.2 % (0–1.3)) a Stenotrophomonas maltophilia resistant towards co-trimoxazole was isolated. No carbapenemase producing Enterobacteriaceae (CPE), multi-resistant Acinetobacter species or multi-resistant Pseudomonas aeruginosa were isolated. The ESBL genes found were bla CTX-M-1 (n = 4, 25.0 %), bla CTX-M-15 (n = 3, 18.8 %), bla CTX-M-27 (n = 2, 12.5 %), bla CTX-M-14b (n = 2, 12.5 %), bla CTX-M-9 (n = 2, 12.5 %), bla CTX-M-14 (n = 1, 6.3 %), bla CTX-M-3 (n = 1, 6.3 %), bla SHV-11 (n = 1, 6.3 %) and bla SHV-12 (n = 1, 6.3 %). Being known HR-GNR positive in the past was the only significant associated risk factor for HR-GNR positivity, odds ratio (95 % CI): 7.32 (1.82–29.35), p-value = 0.005. Similar ESBL prevalence rates and genotypes (3.5 %) were found in comparison to other Dutch studies. When previously HR-GNR positive patients are readmitted, they should be screened for HR-GNR colonization since colonization with GR-GNRs could be prolonged. We recommend for future studies to include all defined HR-GNRs in addition to ESBLs in prevalence studies, in order to obtain a more comprehensive overview of colonization with HR-GNRs.

17 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SESjoerd M. Euser
Sjoerd M. Euser
SASem Aronson
Sem Aronson
IMIrene Manders
Irene Manders
SLSteven van Lelyveld
Steven van Lelyveld
BHBjorn Herpers
Bjorn Herpers
DSDennis Souverein
Dennis Souverein
Objective: To describe the SARS-CoV-2 viral load distribution in different patient groups and age categories. Methods: All SARS-CoV-2 RT-PCR results from nasopharyngeal (NP) and oropharyngeal (OP) swabs (first PCR from unique patients only) that were collected between January 1 and December 1, 2020, predominantly in the Public Health Services regions Kennemerland and Hollands Noorden, province of North Holland, the Netherlands were included in this study. Swabs were derived from patients with respiratory symptoms who were presented at the general practitioner (GP), hospital, or hospital health care workers (HCWs) of four regional hospitals, nursing home residents and HCWs of multiple nursing homes, and in majority (>75%) from Public Health testing facilities of the two Public Health Services. SARS-CoV-2 PCR crossing point (Cp) values were used to estimate viral loads (higher Cp-values indicate lower viral loads). Results: In total, 278.455 unique patients were tested of whom 9·1% (n=25.374) were SARS-CoV-2 positive. As there were differences in viral load distribution between tested populations, further analyses focused on PCRs performed by public health services (n=211.914) where sampling and inclusion were uniform. These data reveal a clear relation between age and SARS-CoV-2 viral load, with especially children aged<12 years showing lower viral loads than shown in adults (β: −0·03, 95CI% −0·03 to −0·02, p79 years) and youngest (<12 years) population differed by over 4 PCR cycles, suggesting approximately a 16-fold difference in viral load. In addition, the proportion of children aged 30) was significantly higher compared to the other patients (31·1% vs. 17·2%, p-value<0.001). Conclusion: We observed that in patients tested by Public Health Services, SARS-CoV2 viral load increases significantly with age. Previous studies suggest that young children (<12 years) play a limited role in SARS-CoV-2 transmission. Currently, the relation between viral load and infectivity is not yet well understood, and further studies should elucidate whether the lower viral load in children is indeed related to their suggested limited role in SARS-CoV-2 transmission. Moreover, as rapid antigen tests are less sensitive than PCR, these results suggest that SARS-CoV-2 antigen tests could have lower sensitivity in children than in adults.

27 March 2015 in Future Microbiology
Verified
Journal Article
Closed access
BHBjorn Herpers
Bjorn Herpers
Bjorn Lars Herpers speaks to Natasha Leeson, Commissioning Editor: Bjorn Lars Herpers was born on 16 February 1974 in Schaesberg. In 1992 he graduated summa cum laude at Gymnasium Rolduc in Kerkrade (The Netherlands) and started to study medical biology at the University of Utrecht. After 3 years, he started to study medicine as well. He graduated cum laude in medical biology in 1999 and obtained his medical degree in 2001. After 1 year of residency in internal medicine at Gooi-Noord Hospital under supervision of DW Erkelens and P Niermeier, he switched to a residency in medical microbiology at the University Medical Center Utrecht and the St Antonius Hospital Nieuwegein under supervision of J Verhoef and B M de Jongh. During his residency, he started to work on his thesis on genetic polymorphisms in MBL and L-ficolin, two complement-activating pattern recognition receptors. In 2009 he became a medical microbiologist and joined the staff at the Regional Public Health Laboratory Kennemerland in Haarlem. Since 2012, he has been involved in clinical research on endolysin therapy in collaboration with Micreos in Bilthoven.

26 June 2017 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
DSDennis Souverein
Dennis Souverein
SESjoerd M. Euser
Sjoerd M. Euser
BHBjorn Herpers
Bjorn Herpers
CHCorry Hattink
Corry Hattink
PHPatricia Houtman
Patricia Houtman
JBJeroen W. Den Boer
Jeroen W. Den Boer
Many Highly Resistant Gram Negative Rod (HR-GNR) positive patients are found unexpectedly in clinical cultures, besides patients who are screened and isolated based on risk factors. As unexpected HR-GNR positive patients are isolated after detection, transmission to contact patients possibly occurred. The added value of routine contact tracing in such situations within hospitals with standard hygiene precautions is unknown. In 2014, this study was performed as a prospective cohort study. Index patients were defined as those tested unexpectedly HR-GNR positive in clinical cultures to diagnose a possible infection and were nursed under standard hygiene precautions before tested positive. After detection they were nursed in contact isolation. Contact patients were still hospitalized and shared the same room with the index patient for at least 12 h. HR-GNR screening was performed by culturing a rectal and throat swab. Clonal relatedness of HR-GNR isolates was determined using whole genome sequencing (WGS). Out of 152 unexpected HR-GNR positive patients, 35 patients (23.0%) met our inclusion criteria for index patient. ESBL E. coli was found most frequently (n = 20, 57.1%), followed by Q&A E. coli (n = 10, 28.6%), ESBL K. pneumoniae (n = 3, 8.5%), ESBL R. ornithinolytica (n = 1, 2.9%) and multi resistant P. aeruginosa (n = 1, 2.9%). After contact tracing, 69 patients were identified as contact patient of an index patient, with a median time between start of contact and sampling of 3 days. None were found HR-GNR positive by nosocomial transmission. In a local setting within hospitals with standard hygiene precautions, routine contact tracing among unexpected HR-GNR positive patients may be replaced by appropriate surveillance as we found no nosocomial transmission in short term contacts.

2 November 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
IMIrene G. Manders
Irene G. Manders
DCDarya Comello
Darya Comello
DSDennis Souverein
Dennis Souverein
SESjoerd M. Euser
Sjoerd M. Euser
BHBjorn Herpers
Bjorn Herpers
SLSteven van Lelyveld
Steven van Lelyveld
Background/Objectives: In 2022, Spaarne Gasthuis hospital implemented an outpatient parenteral antimicrobial therapy (OPAT) programme, including mandatory infectious disease (ID) specialist assessment and integrated structured workflow, aiming to improve quality of care, optimize antimicrobial use, and reduce healthcare costs. Our objective was to evaluate the impact of the OPAT programme on patient outcomes (IV duration, clinical response, adverse clinical outcomes, timely peripherally inserted central catheter (PICC) removal), antimicrobial stewardship parameters, and healthcare costs. Methods: This retrospective before–after cohort study used electronic health record data to compare patients treated with outpatient parenteral antimicrobial therapy before (2019) and after (August 2022–December 2024) OPAT programme implementation. Using linear and logistic regression analyses, the association between the independent variable (pre-OPAT vs. OPAT) and outcomes were assessed and adjusted for potential confounders (sex, age, department, primary and additional indications). Cost analysis was performed, and ID specialist-recommended therapy adjustments were evaluated. Results: In total, 529 patients were included: 118 in the pre-OPAT group, and 411 in the OPAT group. In 36.3% of OPAT cases, therapy was adjusted, thereby optimizing antimicrobial stewardship. The OPAT programme was associated with significantly shorter IV therapy duration of 13.97 (mean) days (95%CI −9.15–−18.79; p < 0.001), significantly less meropenem use (p < 0.001), and significantly less adverse clinical outcomes (OR 0.58, 95%CI 0.37–0.92; p = 0.021), whereas no significant difference was found in clinical response (OR 1.22; 95%CI 0.67–2.32; p = 0.527). The programme led to cost savings of 3.343 EUR per patient. Conclusions: The OPAT programme optimized antimicrobial use and reduced IV therapy duration, adverse clinical outcomes, and healthcare costs.